The key mechanism induced by TPS® is mechanotransduction. Specifically, this stimulation modality has been shown to promote growth factor expression, primarily VEGF 1, 2, improve cerebral blood flow, promote formation of new blood vessels (angiogenesis), and nerve regeneration. An additional effect is the release of nitric oxide (NO) 3, which leads to direct vasodilation and improved blood circulation.
The following biological effects of TPS® have been reported thus far:
The Neurolith device has been rigorously validated in clinical trials. The system received European Union (CE) approval for the treatment of a neurological disorder in 2018. Several other international regulatory approvals are underway. The system is currently investigational (research use) in US and Canada. The indications for which Neurolith is currently being tested for include Spinal Cord Injury, Stroke, Parkinson’s, Alzheimer’s Disease, Unresponsive Wakefulness, and many more.
Neurolith by Storz Medical is exclusively distributed in the US and Canada by Soterix Medical. Neurolith has European Union (CE) approval.